AU2021222339B2 - A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent - Google Patents
A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agentInfo
- Publication number
- AU2021222339B2 AU2021222339B2 AU2021222339A AU2021222339A AU2021222339B2 AU 2021222339 B2 AU2021222339 B2 AU 2021222339B2 AU 2021222339 A AU2021222339 A AU 2021222339A AU 2021222339 A AU2021222339 A AU 2021222339A AU 2021222339 B2 AU2021222339 B2 AU 2021222339B2
- Authority
- AU
- Australia
- Prior art keywords
- cisplatin
- fluorouracil
- lomustine
- artemisinin
- carboplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20158341.6 | 2020-02-19 | ||
| EP20158341.6A EP3868372A1 (en) | 2020-02-19 | 2020-02-19 | A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer |
| PCT/EP2021/054039 WO2021165405A1 (en) | 2020-02-19 | 2021-02-18 | A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021222339A1 AU2021222339A1 (en) | 2022-07-28 |
| AU2021222339B2 true AU2021222339B2 (en) | 2026-05-21 |
Family
ID=69779738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021222339A Active AU2021222339B2 (en) | 2020-02-19 | 2021-02-18 | A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230121771A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3868372A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7719787B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102988319B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114786661A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021222339B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022014692A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165208A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3989961T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2972799T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3989961T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294856A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3989961T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3989961T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021165405A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220184234A1 (en) * | 2020-11-30 | 2022-06-16 | Sonalasense, Inc. | Metabolic targeting of low grade tumors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018082120A1 (zh) * | 2016-11-04 | 2018-05-11 | 吉林省北方医药有限责任公司 | 一种移动终端设备 |
| CN108635581A (zh) * | 2018-05-23 | 2018-10-12 | 昆药集团股份有限公司 | 一种组合物及其在制备治疗肿瘤的药物中的应用 |
| WO2019141988A1 (en) * | 2018-01-17 | 2019-07-25 | St George's Hospital Medical School | Combination therapy for treatment of leukemia |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122006000051I1 (de) | 1995-03-10 | 2007-01-04 | Photocure Asa | Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie |
| GB0018528D0 (en) | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
| TWI482621B (zh) | 2009-12-23 | 2015-05-01 | Sigma Tau Ind Farmaceuti | 青蒿素基藥物與其他化學治療劑的抗癌組合物 |
| JP2011225471A (ja) | 2010-04-16 | 2011-11-10 | Univ Of Tsukuba | 抗癌剤の効果増強剤 |
| US10925963B2 (en) * | 2015-06-22 | 2021-02-23 | Washington University | Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor |
| CN105963244A (zh) | 2016-01-15 | 2016-09-28 | 赵鸣 | 注射用青蒿琥酯制剂及其应用 |
| CN108570089B (zh) * | 2017-04-28 | 2019-10-29 | 云白药征武科技(上海)有限公司 | 双氢青蒿素-甾体结合物及其制备方法和应用 |
-
2020
- 2020-02-19 EP EP20158341.6A patent/EP3868372A1/en active Pending
-
2021
- 2021-02-18 EP EP21705541.7A patent/EP3989961B1/en active Active
- 2021-02-18 CA CA3165208A patent/CA3165208A1/en active Pending
- 2021-02-18 FI FIEP21705541.7T patent/FI3989961T3/fi active
- 2021-02-18 PL PL21705541.7T patent/PL3989961T3/pl unknown
- 2021-02-18 ES ES21705541T patent/ES2972799T3/es active Active
- 2021-02-18 JP JP2022550755A patent/JP7719787B2/ja active Active
- 2021-02-18 US US17/801,021 patent/US20230121771A1/en active Pending
- 2021-02-18 AU AU2021222339A patent/AU2021222339B2/en active Active
- 2021-02-18 IL IL294856A patent/IL294856A/en unknown
- 2021-02-18 KR KR1020227032196A patent/KR102988319B1/ko active Active
- 2021-02-18 WO PCT/EP2021/054039 patent/WO2021165405A1/en not_active Ceased
- 2021-02-18 BR BR112022014692A patent/BR112022014692A2/pt unknown
- 2021-02-18 CN CN202180007033.7A patent/CN114786661A/zh active Pending
- 2021-02-18 PT PT217055417T patent/PT3989961T/pt unknown
- 2021-02-18 DK DK21705541.7T patent/DK3989961T3/da active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018082120A1 (zh) * | 2016-11-04 | 2018-05-11 | 吉林省北方医药有限责任公司 | 一种移动终端设备 |
| WO2019141988A1 (en) * | 2018-01-17 | 2019-07-25 | St George's Hospital Medical School | Combination therapy for treatment of leukemia |
| CN108635581A (zh) * | 2018-05-23 | 2018-10-12 | 昆药集团股份有限公司 | 一种组合物及其在制备治疗肿瘤的药物中的应用 |
Non-Patent Citations (5)
Also Published As
| Publication number | Publication date |
|---|---|
| PT3989961T (pt) | 2024-02-26 |
| WO2021165405A1 (en) | 2021-08-26 |
| DK3989961T3 (da) | 2024-01-29 |
| JP2023514426A (ja) | 2023-04-05 |
| IL294856A (en) | 2022-09-01 |
| JP7719787B2 (ja) | 2025-08-06 |
| BR112022014692A2 (pt) | 2022-09-20 |
| KR102988319B1 (ko) | 2026-07-07 |
| CN114786661A (zh) | 2022-07-22 |
| EP3868372A1 (en) | 2021-08-25 |
| US20230121771A1 (en) | 2023-04-20 |
| EP3989961A1 (en) | 2022-05-04 |
| FI3989961T3 (fi) | 2024-02-14 |
| AU2021222339A1 (en) | 2022-07-28 |
| KR20220143097A (ko) | 2022-10-24 |
| PL3989961T3 (pl) | 2024-04-08 |
| CA3165208A1 (en) | 2021-08-26 |
| EP3989961B1 (en) | 2023-11-22 |
| ES2972799T3 (es) | 2024-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12023328B2 (en) | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | |
| US11639335B2 (en) | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | |
| KR102630889B1 (ko) | 키나제를 조절하는 화합물의 고형 형태 | |
| US8143247B2 (en) | Combinations for the treatment of diseases involving cell proliferation | |
| CA2773838C (en) | Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer | |
| CN116096704A (zh) | 用于治疗癌症的组合疗法 | |
| US20210070712A1 (en) | Dimeric Quinacrine Derivatives As Autophagy Inhibitors For Cancer Therapy | |
| CN101406473A (zh) | 二氢嘧啶化合物的用途及含其的药物组合物 | |
| AU2012271814A1 (en) | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm | |
| JP2017519019A (ja) | mdm2阻害剤の間欠投与 | |
| CN103687853A (zh) | 新型双氨基喹啉化合物及其制备的药物组合物和它们的用途 | |
| EP3697767B1 (en) | Compounds and methods for treating cancer | |
| CN111655669A (zh) | 治疗包括运动神经元疾病的神经紊乱的组合物和方法 | |
| EP3989961B1 (en) | A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent | |
| KR20180037975A (ko) | 포도막 흑색종을 치료하기 위한 mdm2 억제제 | |
| RU2847295C1 (ru) | Фармацевтическая комбинация соединения артемизинина, 5- аминолевулиновой кислоты или метил-5-аминолевулиновой кислоты и химиотерапевтического агента | |
| WO2005089496A2 (en) | Methods for the treatment of synucleinopathies | |
| HK40074153A (en) | A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent | |
| HK40074153B (en) | A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent | |
| WO2021046178A1 (en) | Compounds and methods for treating cancer | |
| TW201315470A (zh) | 吡咯並喹啉基-吡咯啶-2,5-二酮調製劑類及製備和使用彼等之方法 | |
| WO2021046220A1 (en) | Compounds and methods for treating cancer | |
| HK40113709A (en) | Therapeutic combinations comprising ubiquitin specific-processing protease 1 (usp1) inhibitors and chemotherapy agents | |
| EA052090B1 (ru) | Композиции 1-(4-бром-5-(1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил)-2-фторфенил)-3-фенилмочевины | |
| HK40031775A (en) | Compounds and methods for treating cancer |